Oxford - Fibrates in Aortic Stenosis

NCT ID: NCT05256758

Last Updated: 2022-02-25

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 67 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-29
• Study Completion Date: 2022-03-31

Brief Summary

Aortic stenosis (AS) is characterised by left ventricular (LV) hypertrophy and altered myocardial substrate metabolism. Peroxisome proliferator-activated receptor (PPARα), a regulator of lipid metabolism is deactivated in pressure overload hypertrophy such as in AS and can lead to dysregulation of fatty acid oxidation, myocardial triglyceride accumulation (steatosis) and lipotoxicity. The investigators propose a proof-of-concept study to investigate the effect of altering myocardial triglyceride (MTG) using a PPARα agonist, fenofibrate on cardiac physiology in patients with asymptomatic moderate-severe AS. The primary endpoint is a change in MTG assessed by magnetic resonance spectroscopy at baseline and after 6 months of treatment. Exploratory endpoints are changes in cardiac physiology including myocardial deformation (strain) as assessed by cardiac magnetic resonance imaging. The investigators hypothesise that pharmacological reduction of MTG with a PPARα agonist will result in steatosis regression and changes in cardiac physiology.

Detailed Description

This is a single-centre, proof-of-concept study to investigate the effect of altering MTG content using fenofibrate on cardiac physiology in patients with asymptomatic moderate-severe AS. All patients will participate in a randomised, double-blind, placebo- controlled design for 6 months. AS will be graded according to the British Society of Echocardiography's transthoracic echocardiography guidelines. Sixty two eligible patients will be recruited in total, of which forty nine patients will be randomised to receive 200 mg daily oral fenofibrate and thirteen patients will receive matching placebo for 6 months. All patients will undergo 1H-MRS to assess MTG, 31P-MRS to assess myocardial energetic (Phosphocreatine-to-ATP ratio - PCr/ATP), standard cardiac magnetic resonance imaging to assess LV strain, LV mass, late gadolinium enhancement (fibrosis), physiological exercise assessments to measure maximum oxygen consumption (VO2 max) and 6-minute walking distance. Bloods will be drawn for cholesterol, renal and liver function, glucose and free fatty acids. All tests will be done at baseline and after 6 months' treatment with fenofibrate/placebo.

Conditions

Aortic Valve Stenosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: TRIPLE

Study Groups

OxFAST Fibrate group

49 patients randomised to receive fenofibrate 200mg capsules.

Group Type: EXPERIMENTAL

Fenofibrate Capsules

Intervention Type: DRUG

49 patients randomised to receive fenofibrate for 6 months.

OxFAST placebo group

13 patients randomised to receive placebo will act as controls.

Group Type: PLACEBO_COMPARATOR

Placental Lactogen

Intervention Type: DRUG

13 patients randomised to receive placebo for 6 months.

Interventions

Fenofibrate Capsules

49 patients randomised to receive fenofibrate for 6 months.

Intervention Type: DRUG

Placental Lactogen

13 patients randomised to receive placebo for 6 months.

Intervention Type: DRUG

Other Intervention Names

Fenofibrate

Eligibility Criteria

Inclusion Criteria

• Asymptomatic moderate to severe AS (with at least two of the following: aortic valve area <1.5 cm2, peak pressure gradient >36 mmHg or mean pressure gradient >25 mmHg)
• Not planned aortic valve replacement or transcatheter aortic valve implantation (TAVI)
• Age >18
• No other significant valvular pathology
• No contraindication to magnetic resonance imaging.

Exclusion Criteria

• Known coronary artery disease, history of angina, myocardial infarction or presence of regional wall motion abnormalities
• Other underlying cardiomyopathy
• Left ventricular ejection fraction<50%
• Uncontrolled hypertension
• Diabetes Mellitus
• Liver impairment
• Pregnancy and lactation
• Body mass index >35 kg/m2
• Renal impairment (eGFR<30 ml/min)
• Intolerance to or concurrent use of fibrates or PPARα agonists.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

British Heart Foundation

OTHER

Sponsor Role: collaborator

University of Oxford

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mahmod

Role: PRINCIPAL_INVESTIGATOR

University of Oxford

Locations

OUH NHS trust

Oxford, , United Kingdom

Countries

United Kingdom

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

OxFAST

Identifier Type: -

Identifier Source: org_study_id